Drugs that treat diseases of the retina, such as wet age-related macular degeneration (wet AMD), are treated with well-known brands. Physicians, patients and payers have relatively clear expectations for these products. But a coming wave of biosimilars in Europe, the U.S. and other markets could radically transform the treatment ecosystem.
This example provides an opportunity to understand and prepare for the market transition for biosimilars ahead. By looking at the history of biosimilar introductions in other therapeutic areas, we can find valuable lessons valuable to biosimilar companies and brand owners alike.
Download the White Paper Below.
